Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Spero Therapeutics to hold a KOL pharmaceutical update conference call » 11:25
09/30/20
09/30
11:25
09/30/20
11:25
SPRO

Spero Therapeutics

$10.96 /

+1.04 (+10.48%)

Management, along with…

Management, along with Key Opinion Leader Dr. Keith Kaye of the University of Michigan Medical School, discuss oral tebipenem HBr for treatment of complicated urinary tract infections on a conference call to be held on September 30 at 11:30 am. Webcast Link

ShowHide Related Items >><<
SPRO Spero Therapeutics
$10.96 /

+1.04 (+10.48%)

SPRO Spero Therapeutics
$10.96 /

+1.04 (+10.48%)

09/29/20 Evercore ISI
Spero Therapeutics initiated with an Outperform at Evercore ISI
09/08/20 Stifel
Spero Therapeutics price target raised to $25 from $21 at Stifel
05/11/20 H.C. Wainwright
Spero Therapeutics price target raised to $28 from $25 at H.C. Wainwright
11/05/19 H.C. Wainwright
Spero Therapeutics price target raised to $35 from $28 at H.C. Wainwright
SPRO Spero Therapeutics
$10.96 /

+1.04 (+10.48%)

  • 11
    Sep
SPRO Spero Therapeutics
$10.96 /

+1.04 (+10.48%)

Conference/Events
Spero Therapeutics to hold a KOL pharmaceutical update conference call » 04:55
09/30/20
09/30
04:55
09/30/20
04:55
SPRO

Spero Therapeutics

$9.93 /

+0.63 (+6.77%)

Management, along with…

Management, along with Key Opinion Leader Dr. Keith Kaye of the University of Michigan Medical School, discuss oral tebipenem HBr for treatment of complicated urinary tract infections on a conference call to be held on September 30 at 11:30 am. Webcast Link

ShowHide Related Items >><<
SPRO Spero Therapeutics
$9.93 /

+0.63 (+6.77%)

SPRO Spero Therapeutics
$9.93 /

+0.63 (+6.77%)

09/29/20 Evercore ISI
Spero Therapeutics initiated with an Outperform at Evercore ISI
09/08/20 Stifel
Spero Therapeutics price target raised to $25 from $21 at Stifel
05/11/20 H.C. Wainwright
Spero Therapeutics price target raised to $28 from $25 at H.C. Wainwright
11/05/19 H.C. Wainwright
Spero Therapeutics price target raised to $35 from $28 at H.C. Wainwright
SPRO Spero Therapeutics
$9.93 /

+0.63 (+6.77%)

  • 11
    Sep
SPRO Spero Therapeutics
$9.93 /

+0.63 (+6.77%)

Initiation
Spero Therapeutics initiated with an Outperform at Evercore ISI » 09:39
09/29/20
09/29
09:39
09/29/20
09:39
SPRO

Spero Therapeutics

$9.30 /

-0.24 (-2.52%)

Evercore ISI analyst Josh…

Evercore ISI analyst Josh Schimmer initiated coverage of Spero Therapeutics with an Outperform rating and $70 price target. Spero's current valuation implies that investors don't see an unmet need for tebipenem, although specialists with whom he has spoken said they are out of outpatient drugs for a large/growing group of patients and call Spero's tebipenem "the next Zyvox," according to Schimmer. In early trading on Tuesday, Spero shares are up $1.45, or 15.7%, to $10.76.

ShowHide Related Items >><<
SPRO Spero Therapeutics
$9.30 /

-0.24 (-2.52%)

SPRO Spero Therapeutics
$9.30 /

-0.24 (-2.52%)

09/08/20 Stifel
Spero Therapeutics price target raised to $25 from $21 at Stifel
05/11/20 H.C. Wainwright
Spero Therapeutics price target raised to $28 from $25 at H.C. Wainwright
11/05/19 H.C. Wainwright
Spero Therapeutics price target raised to $35 from $28 at H.C. Wainwright
10/03/19 Janney Montgomery Scott
Spero price target raised to $31 from $27 at Janney Montgomery Scott
SPRO Spero Therapeutics
$9.30 /

-0.24 (-2.52%)

  • 11
    Sep
SPRO Spero Therapeutics
$9.30 /

-0.24 (-2.52%)

Over a month ago
Conference/Events
Spero Therapeutics to hold a KOL pharmaceutical update conference call » 17:40
09/24/20
09/24
17:40
09/24/20
17:40
SPRO

Spero Therapeutics

$9.36 /

-0.03 (-0.32%)

Management, along with…

Management, along with Key Opinion Leader Dr. Keith Kaye of the University of Michigan Medical School, discuss oral tebipenem HBr for treatment of complicated urinary tract infections on a conference call to be held on September 30 at 11:30 am. Webcast Link

ShowHide Related Items >><<
SPRO Spero Therapeutics
$9.36 /

-0.03 (-0.32%)

SPRO Spero Therapeutics
$9.36 /

-0.03 (-0.32%)

09/08/20 Stifel
Spero Therapeutics price target raised to $25 from $21 at Stifel
05/11/20 H.C. Wainwright
Spero Therapeutics price target raised to $28 from $25 at H.C. Wainwright
11/05/19 H.C. Wainwright
Spero Therapeutics price target raised to $35 from $28 at H.C. Wainwright
10/03/19 Janney Montgomery Scott
Spero price target raised to $31 from $27 at Janney Montgomery Scott
SPRO Spero Therapeutics
$9.36 /

-0.03 (-0.32%)

  • 11
    Sep
SPRO Spero Therapeutics
$9.36 /

-0.03 (-0.32%)

Hot Stocks
Spero Therapeutics to host KOL call on oral tebipenem HBr » 08:32
09/24/20
09/24
08:32
09/24/20
08:32
SPRO

Spero Therapeutics

$9.40 /

-0.355 (-3.64%)

Spero Therapeutics…

Spero Therapeutics announced it will host a key opinion leader call on oral tebipenem HBr for the treatment of complicated urinary tract infections on Wednesday, September 30, 2020 at 11:30 a.m. Eastern Time. The call will feature a presentation by KOL Keith Kaye, MD, MPH, University of Michigan Medical School, who will discuss the current treatment landscape and unmet medical need in complicated urinary tract infections. Dr. Kaye will be available to answer questions during the call. Spero's management team will also discuss the recently announced positive top-line data from Spero's ADAPT-PO Phase 3 clinical trial of oral tebipenem HBr for the treatment of cUTI and acute pyelonephritis. The ADAPT-PO trial met its primary endpoint of demonstrating that oral tebipenem HBr is statistically non-inferior to intravenous ertapenem, the most commonly used carbapenem for the treatment of cUTI and AP.

ShowHide Related Items >><<
SPRO Spero Therapeutics
$9.40 /

-0.355 (-3.64%)

SPRO Spero Therapeutics
$9.40 /

-0.355 (-3.64%)

09/08/20 Stifel
Spero Therapeutics price target raised to $25 from $21 at Stifel
05/11/20 H.C. Wainwright
Spero Therapeutics price target raised to $28 from $25 at H.C. Wainwright
11/05/19 H.C. Wainwright
Spero Therapeutics price target raised to $35 from $28 at H.C. Wainwright
10/03/19 Janney Montgomery Scott
Spero price target raised to $31 from $27 at Janney Montgomery Scott
SPRO Spero Therapeutics
$9.40 /

-0.355 (-3.64%)

  • 11
    Sep
SPRO Spero Therapeutics
$9.40 /

-0.355 (-3.64%)

On The Fly
Fly Intel: Pre-market Movers » 09:03
09/11/20
09/11
09:03
09/11/20
09:03
NOG

Northern Oil and Gas

$0.52 /

-0.0465 (-8.19%)

, SLGL

Sol-Gel Technologies

$7.62 /

-0.005 (-0.07%)

, IPOB

Social Capital Hedosophia Holdings II

$12.48 /

+0.56 (+4.70%)

, PTON

Peloton

$87.85 /

-3.35 (-3.67%)

, ORCL

Oracle

$56.83 /

-0.145 (-0.25%)

, FARM

Farmer Bros.

$6.15 /

+0.19 (+3.19%)

, CHWY

Chewy

$59.70 /

-1.91 (-3.10%)

, SVRA

Savara

$1.35 /

+0.02 (+1.50%)

, AMRS

Amyris

$3.13 /

+ (+0.00%)

, SPRO

Spero Therapeutics

$11.21 /

-1.61 (-12.56%)

Check out this morning's…

ShowHide Related Items >><<
SVRA Savara
$1.35 /

+0.02 (+1.50%)

SPRO Spero Therapeutics
$11.21 /

-1.61 (-12.56%)

SLGL Sol-Gel Technologies
$7.62 /

-0.005 (-0.07%)

PTON Peloton
$87.85 /

-3.35 (-3.67%)

ORCL Oracle
$56.83 /

-0.145 (-0.25%)

NOG Northern Oil and Gas
$0.52 /

-0.0465 (-8.19%)

FARM Farmer Bros.
$6.15 /

+0.19 (+3.19%)

CHWY Chewy
$59.70 /

-1.91 (-3.10%)

AMRS Amyris
$3.13 /

+ (+0.00%)

NOG Northern Oil and Gas
$0.52 /

-0.0465 (-8.19%)

08/27/20 Roth Capital
Northern Oil and Gas initiated with a Buy at Roth Capital
07/27/20 Seaport Global
Northern Oil and Gas initiated with a Buy at Seaport Global
07/01/20 Truist
Northern Oil and Gas upgraded to Buy from Hold at SunTrust
07/01/20 Truist
Northern Oil and Gas upgraded to Buy from Hold at SunTrust
SLGL Sol-Gel Technologies
$7.62 /

-0.005 (-0.07%)

03/26/20 H.C. Wainwright
Sol-Gel Technologies price target lowered to $21 from $26 at H.C. Wainwright
02/05/20 JMP Securities
Sol-Gel on track for two drug filings this year, says JMP Securities
12/31/19 H.C. Wainwright
Sol-Gel Technologies price target raised to $26 from $23 at H.C. Wainwright
12/31/19 BMO Capital
Sol-Gel Technologies' Twyneo result has best-in-class profile, says BMO Capital
IPOB Social Capital Hedosophia Holdings II
$12.48 /

+0.56 (+4.70%)

PTON Peloton
$87.85 /

-3.35 (-3.67%)

09/11/20 MKM Partners
Peloton price target raised to $90 from $70 at MKM Partners
09/11/20 BMO Capital
Peloton price target raised to $33 from $26 at BMO Capital
09/11/20 JPMorgan
Peloton price target raised to $125 from $105 at JPMorgan
09/11/20 Needham
Peloton price target raised to $110 from $65 at Needham
ORCL Oracle
$56.83 /

-0.145 (-0.25%)

09/11/20 Societe Generale
Oracle price target raised to $70 from $60 at Societe Generale
09/11/20 RBC Capital
Oracle price target raised to $60 from $51 at RBC Capital
09/11/20 BMO Capital
Oracle price target raised to $63 from $57 at BMO Capital
09/11/20 Morgan Stanley
Oracle price target raised to $62 from $58 at Morgan Stanley
FARM Farmer Bros.
$6.15 /

+0.19 (+3.19%)

03/31/20 B. Riley Securities
Farmer Bros. price target lowered to $8 from $12 at B. Riley FBR
09/12/19 Roth Capital
Farmer Bros. price target lowered to $11 from $20 at Roth Capital
CHWY Chewy
$59.70 /

-1.91 (-3.10%)

09/11/20 JPMorgan
Chewy price target raised to $72 from $70 at JPMorgan
09/11/20 Morgan Stanley
Chewy price target raised to $49 from $45 at Morgan Stanley
09/11/20 Barclays
Chewy price target raised to $60 from $55 at Barclays
09/11/20 Credit Suisse
Chewy price target raised to $62 from $53 at Credit Suisse
SVRA Savara
$1.35 /

+0.02 (+1.50%)

12/30/19 JMP Securities
Data for Savara's Molgradex still several years away, JMP Securities says
AMRS Amyris
$3.13 /

+ (+0.00%)

12/12/19
Fly Intel: Top five analyst initiations
12/12/19 Oppenheimer
Amyris initiated with an Outperform at Oppenheimer with $8 price target
12/11/19 Oppenheimer
Amyris initiated with an Outperform at Oppenheimer
SPRO Spero Therapeutics
$11.21 /

-1.61 (-12.56%)

09/08/20 Stifel
Spero Therapeutics price target raised to $25 from $21 at Stifel
05/11/20 H.C. Wainwright
Spero Therapeutics price target raised to $28 from $25 at H.C. Wainwright
11/05/19 H.C. Wainwright
Spero Therapeutics price target raised to $35 from $28 at H.C. Wainwright
10/03/19 Janney Montgomery Scott
Spero price target raised to $31 from $27 at Janney Montgomery Scott
SVRA Savara
$1.35 /

+0.02 (+1.50%)

SPRO Spero Therapeutics
$11.21 /

-1.61 (-12.56%)

SLGL Sol-Gel Technologies
$7.62 /

-0.005 (-0.07%)

PTON Peloton
$87.85 /

-3.35 (-3.67%)

ORCL Oracle
$56.83 /

-0.145 (-0.25%)

NOG Northern Oil and Gas
$0.52 /

-0.0465 (-8.19%)

FARM Farmer Bros.
$6.15 /

+0.19 (+3.19%)

CHWY Chewy
$59.70 /

-1.91 (-3.10%)

AMRS Amyris
$3.13 /

+ (+0.00%)

  • 11
    Sep
  • 26
    Sep
PTON Peloton
$87.85 /

-3.35 (-3.67%)

ORCL Oracle
$56.83 /

-0.145 (-0.25%)

IPOB Social Capital Hedosophia Holdings II
$12.48 /

+0.56 (+4.70%)

CHWY Chewy
$59.70 /

-1.91 (-3.10%)

SVRA Savara
$1.35 /

+0.02 (+1.50%)

PTON Peloton
$87.85 /

-3.35 (-3.67%)

ORCL Oracle
$56.83 /

-0.145 (-0.25%)

NOG Northern Oil and Gas
$0.52 /

-0.0465 (-8.19%)

CHWY Chewy
$59.70 /

-1.91 (-3.10%)

AMRS Amyris
$3.13 /

+ (+0.00%)

PTON Peloton
$87.85 /

-3.35 (-3.67%)

ORCL Oracle
$56.83 /

-0.145 (-0.25%)

CHWY Chewy
$59.70 /

-1.91 (-3.10%)

AMRS Amyris
$3.13 /

+ (+0.00%)

Syndicate
Spero Therapeutics 8M share Secondary priced at $10.00 » 06:56
09/11/20
09/11
06:56
09/11/20
06:56
SPRO

Spero Therapeutics

$11.21 /

-1.61 (-12.56%)

The deal priced below the…

The deal priced below the last closing price of $11.12. Cowen, Evercore ISI, Cantor Fitzgerald, Oppenheimer and H.C. Wainwright are acting as joint book running managers for the offering.

ShowHide Related Items >><<
SPRO Spero Therapeutics
$11.21 /

-1.61 (-12.56%)

SPRO Spero Therapeutics
$11.21 /

-1.61 (-12.56%)

09/08/20 Stifel
Spero Therapeutics price target raised to $25 from $21 at Stifel
05/11/20 H.C. Wainwright
Spero Therapeutics price target raised to $28 from $25 at H.C. Wainwright
11/05/19 H.C. Wainwright
Spero Therapeutics price target raised to $35 from $28 at H.C. Wainwright
10/03/19 Janney Montgomery Scott
Spero price target raised to $31 from $27 at Janney Montgomery Scott
SPRO Spero Therapeutics
$11.21 /

-1.61 (-12.56%)

  • 11
    Sep
Syndicate
Spero Therapeutics files to sell 8M shares of common stock » 16:34
09/09/20
09/09
16:34
09/09/20
16:34
SPRO

Spero Therapeutics

$12.81 /

-0.31 (-2.36%)

Cowen and Company,…

Cowen and Company, Evercore Group, L.L.C. and Cantor Fitzgerald & Co. are acting as joint book-running managers for the offering. Oppenheimer & Co. is acting as lead manager for the offering, and H.C. Wainwright & Co. is acting as co-manager for the offering.

ShowHide Related Items >><<
SPRO Spero Therapeutics
$12.81 /

-0.31 (-2.36%)

SPRO Spero Therapeutics
$12.81 /

-0.31 (-2.36%)

09/08/20 Stifel
Spero Therapeutics price target raised to $25 from $21 at Stifel
05/11/20 H.C. Wainwright
Spero Therapeutics price target raised to $28 from $25 at H.C. Wainwright
11/05/19 H.C. Wainwright
Spero Therapeutics price target raised to $35 from $28 at H.C. Wainwright
10/03/19 Janney Montgomery Scott
Spero price target raised to $31 from $27 at Janney Montgomery Scott
SPRO Spero Therapeutics
$12.81 /

-0.31 (-2.36%)

Recommendations
Spero Therapeutics price target raised to $25 from $21 at Stifel » 14:43
09/08/20
09/08
14:43
09/08/20
14:43
SPRO

Spero Therapeutics

$12.93 /

+3.94 (+43.83%)

Stifel analyst Stephen…

Stifel analyst Stephen Willey raised the firm's price target on Spero Therapeutics to $25 from $21 and maintained a Buy rating on the shares after the company's Phase 3 ADAPT-PO trial met its primary endpoint. The analyst noted the study results represent a "critically important" de-risking event for the shares. The clinical practice-changing potential of the first oral carbapenem that is dissociated from traditional hospital-based reimbursement constraints should provide Spero the opportunity to rewrite the narrative here, Willey told investors in a research note.

ShowHide Related Items >><<
SPRO Spero Therapeutics
$12.93 /

+3.94 (+43.83%)

SPRO Spero Therapeutics
$12.93 /

+3.94 (+43.83%)

05/11/20 H.C. Wainwright
Spero Therapeutics price target raised to $28 from $25 at H.C. Wainwright
11/05/19 H.C. Wainwright
Spero Therapeutics price target raised to $35 from $28 at H.C. Wainwright
10/03/19 Janney Montgomery Scott
Spero price target raised to $31 from $27 at Janney Montgomery Scott
10/02/19 Oppenheimer
Spero Therapeutics price target lowered to $20 from $30 at Oppenheimer
SPRO Spero Therapeutics
$12.93 /

+3.94 (+43.83%)

Hot Stocks
Spero Therapeutics says Phase 3 ADAPT-PO trial met primary endpoint » 07:35
09/08/20
09/08
07:35
09/08/20
07:35
SPRO

Spero Therapeutics

$8.99 /

-0.18 (-1.96%)

Spero Therapeutics…

Spero Therapeutics announced positive topline results from ADAPT-PO, the pivotal Phase 3 clinical trial evaluating Spero's oral antibiotic candidate, tebipenem HBr, for the treatment of adults with complicated urinary tract infection and acute pyelonephritis. Topline data from the trial demonstrate that oral tebipenem HBr was statistically non-inferior to intravenous ertapenem in the treatment of patients with cUTI and patients with AP. The global Phase 3 ADAPT-PO clinical trial evaluated the safety and efficacy of oral tebipenem HBr versus IV ertapenem for the treatment of adults with cUTI or AP. Results demonstrate that tebipenem HBr was non-inferior compared to ertapenem with respect to the trial's primary endpoint, overall response at the test-of-cure visit in the microbiological-intent-to-treat population. The favorable overall response rates at TOC were 58.8% versus 61.6% for tebipenem HBr and ertapenem, respectively. Clinical cure rates at TOC were high in both treatment groups. Overall response rates were consistent across key subgroups of interest, including age, baseline diagnosis, and presence of bacteremia. Per pathogen microbiological response was balanced across treatment groups for most prevalent uropathogens. Comparative safety data from the 1,372 hospitalized adult patients who enrolled in the trial suggest that tebipenem HBr was well-tolerated, with a safety profile similar to that of ertapene. Treatment emergent adverse events were reported in approximately 26% of patients in both treatment groups. The most commonly reported TEAEs in both treatment groups were diarrhea and headache. Serious TEAEs were infrequent and no deaths were reported in the trial. Three Clostridioides difficile-associated TEAEs were observed in the ertapenem group, while none were observed in the tebipenem HBr group. Emerging data from the tebipenem HBr program, including the ADAPT-PO clinical trial results, will be presented in detail at future scientific meetings and in publications. Tebipenem HBr has been granted Qualified Infectious Disease Product and Fast Track designations by the U.S. Food and Drug Administration for the treatment of cUTI, which may result in expedited review and an option for rolling submission of a New Drug Application. Spero intends to initiate a rolling NDA submission and anticipates completing the NDA submission to the FDA for tebipenem HBr in the second quarter of 2021.

ShowHide Related Items >><<
SPRO Spero Therapeutics
$8.99 /

-0.18 (-1.96%)

SPRO Spero Therapeutics
$8.99 /

-0.18 (-1.96%)

05/11/20 H.C. Wainwright
Spero Therapeutics price target raised to $28 from $25 at H.C. Wainwright
11/05/19 H.C. Wainwright
Spero Therapeutics price target raised to $35 from $28 at H.C. Wainwright
10/03/19 Janney Montgomery Scott
Spero price target raised to $31 from $27 at Janney Montgomery Scott
10/02/19 Oppenheimer
Spero Therapeutics price target lowered to $20 from $30 at Oppenheimer
SPRO Spero Therapeutics
$8.99 /

-0.18 (-1.96%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.